Ahmed Mourad, MBBS, MS

Vitiligo Up-and-Coming Invited Speaker

Speaker Details
  • Presentation Title

    PD-1 and PD-l1 Levels in Vitiligo Patients

  • Summary

    The PD-1/PD-L1 checkpoint is implicated in autoimmune diseases and a high incidence of vitiligo like lesions is reported as an adverse
    effect of PD-1/PD-L1 blockade, raising the possibility of a role for PD-1/PD-L1 checkpoint in vitiligo pathogenesis. We found that PD-1 in marginal biopsies was significantly higher than both in nonlesional biopsies and in controls, while PD-L1 in marginal biopsies was significantly lower than both in nonlesional biopsies and in controls. PD-1 in nonlesional biopsies was significantly higher than in controls and PD-L1 in nonlesional biopsies was significantly lower than in controls. A significant positive correlation was found between marginal and nonlesional PD-1 levels. Our results suggest that the PD-1/PD-L1 checkpoint seems to be implicated in the loss of peripheral tolerance in human vitiligo, with PD-1 being highly expressed on infiltrating T cells yet sufficiently stimulated due to lack of local PD-L1 expression. PD-1 agonists may be of therapeutic value, but need wider scale studies before clinical implementation.

  • Additional Authors

    Prof. Dr. Hanan Rabea Nada
    Professor of Dermatology
    Faculty of Medicine- Cairo University

    A.Prof. Dr. Ghada Mohamad El Hanafi
    Assistant Professor of Dermatology
    Faculty of Medicine- Cairo University

    A.Prof. Dr. Mohamed Abd El-Hady
    Assistant Professor of Dermatology
    Faculty of Medicine - Cairo University

    Prof. Dr. Laila Ahmed Rashed
    Professor of Medical Biochemistry and Molecular Biology
    Faculty of Medicine - Cairo University

  • Disclosures

    No relevant disclosures.

Download Abstract

This abstract can be found in the 2021 VIS Invited and Oral Speakers Abstract book